Pharmacological management of appetite expression in obesity.
For obese individuals, successful weight loss and maintenance are notoriously difficult. Traditional drug development fails to exploit knowledge of the psychological factors that crucially influence appetite, concentrating instead on restrictive criteria of intake and weight reduction, allied to a mechanistic view of energy regulation. Drugs are under development that may produce beneficial changes in appetite expression in the obese. These currently include glucagon-like peptide-1 analogs such as liraglutide, an amylin analog davalintide, the 5-HT(2C) receptor agonist lorcaserin, the monoamine re-uptake inhibitor tesofensine, and a number of combination therapies such as pramlintide and metreleptin, bupropion and naltrexone, phentermine and topiramate, and bupropion and zonisamide. However, the effects of these treatments on eating behavior remain poorly characterized. Obesity is typically a consequence of overconsumption driven by an individual's natural sensitivity to food stimuli and the pleasure derived from eating. Intuitively, these processes should be effective targets for pharmacotherapy, and behavioral analysis can identify drugs that selectively affect desire to eat, enjoyment of eating, satiation or postmeal satiety. Rational interventions designed specifically to modulate these processes could limit the normally aversive consequences of caloric restriction and maximize an individual's capacity to successfully gain control over their appetite.
Halford
Jason C G
JC
School of Psychology, University of Liverpool, Eleanor Rathbone Building, Bedford Street South, Liverpool L69 7ZA, UK. j.c.g.halford@liverpool.ac.uk
Boyland
Emma J
EJ
Blundell
John E
JE
Kirkham
Tim C
TC
Harrold
Joanne A
JA
D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects*; D005247:Feeding Behavior; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000523:psychology; D012527:Satiation; D012701:Serotonin / Q000502:physiology; D058826:Serotonin 5-HT2 Receptor Agonists
D019440:Anti-Obesity Agents; D058826:Serotonin 5-HT2 Receptor Agonists; D012701:Serotonin; D052216:Glucagon-Like Peptide 1